Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Comprehensive clinical development programs being initiated for each investigational candidate
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated